Remegen Biopharmaceutical (Yantai) Co., Ltd. voluntarily disclosed an announcement about Tai.tasirumab achieving the primary study endpoint in Phase III clinical studies of myasthenia gravis.
Announcement from Remegen regarding change of signed registered accountant
Legal opinion on the 2023 Remegen annual shareholder meeting.
Remegen's 2023 Annual Shareholders' Meeting Resolution Announcement
Remegen's 2023 Annual Shareholders Meeting materials.
Legal opinion on the first interim shareholder meeting of Remegen in 2024.
Remegen announces the resolution of the first extraordinary shareholders meeting in 2024.
Announcement of Remegen's Private Investment Fund Settlement Account Opening
Remegen's first interim shareholder meeting materials for 2024.
Notice of Rongchang Biopharmaceutical (Yantai) Co., Ltd. on convening the 2024 First Extraordinary General Meeting of Shareholders
Notice of Rongchang Biopharmaceutical (Yantai) Co., Ltd. on convening the 2023 Annual General Meeting of Shareholders
Announcement of Rongchang Biotech on regulatory measures or penalties imposed by securities regulators and stock exchanges in the last five years
Rongchang Biotech's 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Rongchang Biotech 2023 Internal Control Evaluation Report
Announcement of Rongchang Biopharmaceutical (Yantai) Co., Ltd. on the use of its own funds for cash management
Announcement of Rongchang Biopharmaceutical (Yantai) Co., Ltd. on changing the registered capital, revising the “Articles of Association” and revising some internal management systems
Announcement of Resolutions of Rongchang Biotech\'s Second Extraordinary General Meeting of Shareholders in 2023, the First Class A Shareholders\' Meeting in 2023, and the First Class H Shareholders\' Meeting in 2023
Legal Opinions of Beijing Jindu Law Firm on the 2023 Second Extraordinary General Meeting of Shareholders of Rongchang Biopharmaceuticals (Yantai) Co., Ltd., the first Class A Shareholders\' Meeting in 2023, and the First Class H Shareholders\' Meeting in
Announcement of Rongchang Biopharmaceutical (Yantai) Co., Ltd. on the cancellation of special settlement accounts for some financial products
Rongchang Biotech\'s 2023 Second Extraordinary General Meeting of Shareholders, 2023 First Class A Shareholders\' Meeting, and 2023 First Class H Shareholders\' Meeting Meeting
No Data